BCIQ Profiles

Company Profile Report

Hello RNA

New targets at AACR suggest non-coding RNAs are on the rise

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high level of interest in finding new ways to manipulate immune cells.

Of the 33 emerging targets and 54 new targets that BioCentury identified in abstracts released ahead of this year’s American Association for Cancer Research conference, 13% (11) are non-coding RNAs: ten miRNAs and one long-non-coding RNA (see “New World Opportunities”).


BioCentury grouped the 87 new and emerging molecular targets in abstracts from the 2018 American Association for Cancer Research (AACR) conference into 15 functional categories based on their known or expected in vivo activities. New targets are defined as those not mentioned in any previous BioCentury reporting. Emerging targets are those that increased in mentions from zero or one abstract in AACR 2017 to four or more this year. The targets are listed alphabetically, first by new targets then by emerging targets under each category. Numbers represent the number of new and emerging targets in each class. Full target names can be obtained from BioCentury’s BCIQ database.

That stands in stark contrast to last year’s meetings of AACR and the American Society of Hematology (ASH). BioCentury only recorded one new RNA target at each of those meetings.

While cancer therapies have traditionally targeted DNA or proteins, new screening tools are making it easier to identify cancer-associated RNA sequences, both mRNAs and non-coding RNAs.

Moreover, the ability to therapeutically target RNA molecules is becoming a reality as new technologies and modalities gain traction. For instance, researchers have developed at least three CRISPR systems that can target RNA.

Computational and chemical biology tools

Read the full 2854 word article

How to gain access

Continue reading with a
two-week free trial.